PAMINE FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAMINE FORTE (PAMINE FORTE).
Anticholinergic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretory activity.
| Metabolism | Hepatic metabolism (CYP450 enzymes, primarily CYP2D6 and CYP3A4). |
| Excretion | Renal (70% unchanged), biliary/fecal (30%) |
| Half-life | 1.5-2 hours; prolonged in renal impairment |
| Protein binding | 40% bound to albumin |
| Volume of Distribution | 4.2 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 10-25% due to first-pass metabolism; IM: 100% |
| Onset of Action | Oral: 1 hour; IM: 15-30 minutes; IV: 1-2 minutes |
| Duration of Action | 3-4 hours for anticholinergic effects; gastric acid suppression up to 6 hours |
1 tablet (5 mg) orally 4 times daily, before meals and at bedtime.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based adjustments are established; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased adverse effects. |
| Liver impairment | No specific Child-Pugh based modifications are established; use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established; use not recommended. |
| Geriatric use | Elderly patients may be more sensitive to anticholinergic effects; initiate at lowest effective dose, titrate carefully. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PAMINE FORTE (PAMINE FORTE).
| Breastfeeding | Methscopolamine is excreted into breast milk in small amounts; M/P ratio not established. Anticholinergic effects in infants may include constipation, dry mouth, or tachycardia. Use with caution; monitor infant for anticholinergic effects. |
| Teratogenic Risk | PAMINE FORTE (methscopolamine bromide) is an anticholinergic agent. Data on fetal risks in humans are limited. Animal studies have not reported teratogenic effects. First trimester: No well-controlled studies; risk cannot be excluded. Second and third trimesters: Use only if clearly needed; anticholinergics may cause fetal tachycardia, decreased GI motility, and potential respiratory depression in neonates if used near term. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to methscopolamine or any component","Narrow-angle glaucoma","Obstructive uropathy","Obstructive GI tract disease","Severe ulcerative colitis","Myasthenia gravis"]
| Precautions | May cause drowsiness, blurred vision, heat prostration, urinary retention, and constipation. Use with caution in patients with glaucoma, myasthenia gravis, autonomic neuropathy, and renal/hepatic impairment. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate and blood pressure; assess for signs of anticholinergic toxicity (e.g., blurred vision, urinary retention). Fetal monitoring: heart rate surveillance if used near term; evaluate for neonatal anticholinergic effects post-delivery. |
| Fertility Effects | No specific data on fertility impairment in humans. Anticholinergics may theoretically affect reproductive function by altering cholinergic signaling; clinical significance unknown. |